22 October 2015 
EMA/CHMP/489271/2015 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Xalkori 
crizotinib 
On 22 October 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Xalkori. The marketing authorisation holder for this medicinal product is Pfizer Limited. 
The CHMP adopted a new indication as follows: 
‘Xalkori is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive 
advanced non-small cell lung cancer (NSCLC)’. 
For information, the full indications for Xalkori will be as follows: 
‘Xalkori is indicated for the first-line treatment of adults with anaplastic lymphoma kinase 
(ALK)-positive advanced non-small cell lung cancer (NSCLC). 
Xalkori is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK) 
positive advanced non-small cell lung cancer (NSCLC).’ 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
                                                
